Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of propranolol in newborns with retinopathy of prematurity

Conditions: Retinopathy of Prematurity

Summary: the purpose of this study is to determine whether the administration of propranolol is effective in the treatment of the retinopathy of the prematurity.

retinopathy of prematurity (rop) is still a major cause of blindness in children in developed countries around the world, and an increasing cause of blindness in developing countries. the ablation of the retina with photocoagulation by laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of rop. however, the visual outcomes after treatment are often poor. the development of rop depends largely from vascular endothelial growth factor (vegf). the reduction of vegf expression in the neovascular phase might prevent destructive neovascularization in rop. the purpose of this study is to evaluate whether the administration of propranolol is safe and is able to reduce the incidence of blindness by suppressing the neovascular phase of rop compared to a control group receiving conventional laser therapy.

Eligibility criteria:
inclusion criteria: 1. infants who have been screened for rop (≤ 32 weeks gestation) who develop stage 2 rop in zone ii without plus. 2. informed consent from a parent exclusion criteria: 1. newborns with one or more of the following conditions at the enrollment in the study: * heart failure. * recurrent episodes of bradycardia (heart rate less than 90 bpm). * atrio-ventricular block (second or third degree). * significant congenital heart anomaly, not including patent ductus arteriosus, patent foramen ovale or small ventricular septal defect. * hypotension. * renal failure. * cerebral hemorrhage. * other diseases which contraindicate the use of beta-blockers 2. newborns with rop stages more advances than stage 2 in zone ii without plus. 3. informed consent from a parent refused. this will mean that an infant automatically will receive standard laser therapy. no data will be used from an infant without informed consent.

Keywords: newborn retinal diseases angiogenesis modulating agents adrenergic beta-antagonists
comparison of the efficacy of transversus abdominis plane block and erector spinae plane block in postoperative analgesia management after abdominoplasty

Conditions: Abdominoplasty; Postoperative Pain; Transversus Abdominis Plane (TAP) Block; Erector Spinae Plane Block

Summary: introduction: abdominoplasty involves the removal of excess skin and fat from the abdominal region, rectus sheath plication, and umbilical transposition. the number of cosmetic abdominoplasty procedures has been steadily increasing in recent years. due to extensive tissue manipulation and large incisions during surgery, postoperative pain has become a significant concern. studies report that up to 80% of patients experience postoperative pain; however, fewer than half of these patients receive adequate analgesia. improving postoperative pain control has been shown to facilitate early mobilization, reduce hospital length of stay, lower healthcare costs, and enhance patient satisfaction. therefore, ensuring effective postoperative analgesia has become a critical aspect of patient management. transversus abdominis plane (tap) block and erector spinae plane (esp) block are peripheral nerve block techniques that can be used as part of a multimodal analgesia approach for postoperative pain management after abdominoplasty. in this study, we aimed to compare the effects of tap and esp blocks on postoperative pain in patients undergoing abdominoplasty. aim/hypothesis: h0: there is a significant difference in the analgesic efficacy between ultrasound-guided esp and tap blocks in postoperative pain management after abdominoplasty. h1: there is not a significant difference in the analgesic efficacy between ultrasound-guided esp and tap blocks in postoperative pain management after abdominoplasty. materials and methods: our study was designed as a retrospective analysis. patient records and hospital database will be reviewed to identify all patients who underwent abdominoplasty and received tap block or esp block for postoperative analgesia. demographic data including age, gender, weight, height, body mass index (bmi) and american society of anesthesiologists (asa) classification, as well as comorbidities and medications used will be recorded on case report forms. the type of block performed (tap or esp) and postoperative pain scores obtained from pain assessment forms using the numerical rating scale (nrs) at 0, 2, 4, 6, 12 and 24 hours postoperatively will be documented. in addition, data from the patient-controlled analgesia (pca) device will be recorded, including number of doses demanded (dem) and number of doses delivered (del). other parameters such as additional analgesic requirements, postoperative nausea and vomiting, itching and patient satisfaction will also be recorded.


Eligibility criteria:
inclusion criteria: * patients who underwent abdominoplasty and received tap or esp blocks for postoperative analgesia, followed by monitoring with iv pca. exclusion criteria: * cases in which iv pca was not used, vas scoring was unavailable, or complications occurred.
the comparison of dexmedetomidine and midazolam for the sleep in intensive care unit

Conditions: Poor Quality Sleep; Sleep Deprivation; Sleep Arousal Disorders; Delirium

Summary: the investigators are going to compare the sleep quality and quantity between dexmedetomidine group and midazolam group using 24 hour polysomnography in critically ill patients. and the investigators also compare the incidence of delirium between the two groups.

sleep is very important for cognitive and immune function. however, patients in intensive care unit (icu) have a very poor sleep. almost all ventilated patients in intensive care unit (icu) take a sedative drug. in korea, most commonly used sedative drugs are dexmedetomidine and midazolam. the investigators are going to compare the sleep quality and quantity between dexmedetomidine group and midazolam group using 24 hour polysomnography. and the investigators also compare the incidence of delirium between the two groups.

Eligibility criteria:
inclusion criteria: * sedation patients with dexmedetomidine or midazolam * over 18 years old exclusion criteria: * neurologic disease (stroke, seizure, dementia, hypoxic brain damage) * brain infection * alcoholics * major depression disorder, schizophrenia, anxiety disorder * hearing loss
primary care based intervention for the secondary prevention of osteoporotic fractures

Conditions: Osteoporotic Fractures

Summary: background recent evidence has been published about the effectiveness for the secondary prevention of osteoporotic fractures (of) of the hospital-based fracture liaison services. aim to assess the effectiveness of a primary care based intervention in the secondary prevention of of. methodology prospective study of random clusters, defined at the primary-care trust (pct) level. total study follow-up 3 years. sample size 1800 patients. description to launch a defined strategy for the identification of of. to carry out a primary care based intervention about lifestyle, diet and drug prescription, if needed, with an intensive follow-up in the intervention pct vs treatment as usual in the control branch. analysis as the outcome are the new of, a survival analysis will be done. risk factors will be analyzed through cox proportional hazard regression model stratified by age groups. outcomes : * new of ratio in intervention vs control areas. * maintenance of the adherence to the pharmacological and non pharmacological interventions proposed * assessment of cost-effectivity of the intervention


Eligibility criteria:
inclusion criteria: * major of (distal forearm, vertebral, hip, pelvis and humerus * caused by a low impact mechanism exclusion criteria: * high impact mechanism of impact or secondary to other diseases (cancer, paget disease ...) * patients not residing in the area of the targeted primary care practices * patients with an invalidating disease (dementia ...)
apollo(aromatase inhibitor patient compliance program with qol questionaire)

Conditions: Breast Cancer

Summary: to describe patients' compliance of taking aromatase inhibitor as an adjuvant treatment in the postmenopausal, early breast cancer as seen under current practice


Eligibility criteria:
inclusion criteria: * provision of written informed consent * patients with early breast cancer who are scheduled to receive first-line adjuvant endocrine therapy with aromatase inhibitor under the routine clinical practice * histologically or cytologically proven to be hr+(er or pr +) * postmenopausal woman, defined as a woman fulfilling any of the following criteria(by the local guideline): * age \>= 50 years * age \ 12 months and an intact uterus * fsh levels within postmenopausal range (over 30-40 iu/ml), or * having undergone a bilateral oophorectomy. * no other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators exclusion criteria: * recurrence of breast cancer * known hypersensitivity to aromatase inhibitor or to any of the excipients * any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the trial protocol * previous inclusion in the present study * participation in a clinical study during the last 30 days

Keywords: aromatase inhibitor breast cancer compliance naturalistic observational
rct of the efficacy of the ketogenic diet in the treatment of epilepsy

Conditions: Epilepsy

Summary: a study of the efficacy and tolerability of two different ketogenic diets in children with drug resistant epilepsy; children resistant to at least two drugs randomised to reveive diet after baseline or after further 3m control period; in addition randomised to either mct or classical ketogenic diet.


Eligibility criteria:
inclusion criteria: * diagnosis of epilepsy for at least 2 years, resistant to at least two aeds, at least 7 seizures/week

Keywords: epilepsy
multimodal stimulation before and after sacral nerve stimulation for irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: sacral nerve stimulation (sns) has become a well-established treatment for patients with fecal incontinence since 1995. the mechanism of action of sns is still not fully understood but recent studies have shown changes in both colonic motility and rectal sensibility. the investigators have previously shown ibs patients to benefit from sacral nerves stimulation. with the present study, the investigators aim to evaluate if sacral nerve stimulation alters the gastro-colic response in ibs patients.

twenty four patients with ibs-d or ibs-m according to the rome iii criteria, will be enrolled in the study. having meet inclusion criteria, the patients will be examined with multimodal stimulation at baseline and at six weeks in the sacral nerve stimulation test period. during the multimodal stimulation the patients will have impedance planimetry conducted before and after a standardised meal to evaluate on their gastro-colic response without and during sacral nerve stimulation. the patients enrolled in the study will in the same time period participate in another study evaluating subsensory sacral nerve stimulation. a study registered at clinical trials. here patients are randomised to receive either off-subsensory or subsensory-off stimulation in a 2+2-week period followed by 2 weeks of suprasensory stimulation. hereby rendering a stimulation test period of a total of 6 weeks (a permanent electrode is used).

Eligibility criteria:
inclusion criteria: * patients aged over 18 * patients who are psychologically stable and suitable for intervention and able to provide informed consent. * patients who are diagnosed with ibs-d or ibs-m according to the rome iii criteria * minimum average of 40 points in the symptom questionnaire evaluated at baseline exclusion criteria: * overt bowel diseases including inflammatory bowel disease * pregnant or breast feeding * patients who are considered unable to follow the planned programme of the study, including mentally illness or physiological instability * patients who are on medication with known influence on gastrointestinal motility including those for thyroid disease, diabetes mellitus, celiac disease and neurological disease

Keywords: irritable bowel syndrome sacral nerve stimulation gastro-colic response multimodal stimulation
efficacy study of different lens treatments on chinese adolescent myopia

Conditions: Progressive Myopia

Summary: the purpose of this study is to determine the efficacy of different lens treatments (normal spectacle lens, ortho-k, \& myovision) on myopia control in chinese adolescent patients.

different lens treatments include normal spectacle lens, orthokeratology, and myovision (a specially designed spectacle lens commercially available with peripheral defocus controlled as relative myopia). this study is to evaluate the efficacy of these three methods in controlling myopia progression. until now, there is no sufficient clinical evidences to compare different lens treatments.

Eligibility criteria:
inclusion criteria: * adolescent myopia patients * myopic refraction between -1.00d and -4.50d * astigmatism equal or less than -1.50d * normal break up time of tear film (but \> 10s) exclusion criteria: * existence of any ocular diseases except ametropia * hyperopia * severe dry eye

Keywords: progressive myopia contact lenses spectacles
proton magnetic resonance spectroscopy (1h mrs) in evaluating the bone marrow, muscle and adipose tissue on normal and human immunodeficiency virus infected subjects

Conditions: Acquired Immunodeficiency Syndrome; Lipodystrophy

Summary: magnetic resonance spectroscopy (mrs) is commonly applied in medicine with 1h proton or 31-phosphorus spectra. the proton mrs is often used in evaluating the central nervous system and 31p mrs is used in muscular diseases or neoplasms. however, the proton mrs is also considered to be applied to the musculoskeletal system because of its profound amount of protons. ballon used the steam technique, and schick used the press technique, to investigate the lipid and water spectra of the bone marrow and also correlated those with hematological diseases and post-treatment effects. schellinger et al. used the steam sequence to calculate the lipid content of the vertebral bone marrow and found that it was influenced according to age and sex. the investigator had used the proton mrs to evaluate the lipid and water spectra of the femoral head and revealed its significance in predicting avascular necrosis of the femoral head. according to the above research literature, the investigators considered further investigation of the proton mrs in evaluating the musculoskeletal system.

magnetic resonance spectroscopy (mrs) is commonly applied in medicine with 1h proton or 31-phosphorus spectra. the proton mrs is often used in evaluating the central nervous system and 31p mrs is used in muscular diseases or neoplasms. however, the proton mrs is also considered to be applied to the musculoskeletal system because of its profound amount of protons. ballon used the steam technique, and schick used the press technique, to investigate the lipid and water spectra of the bone marrow and also correlated those with hematological diseases and post-treatment effects. schellinger et al. used the steam sequence to calculate the lipid content of the vertebral bone marrow and found that it was influenced according to age and sex. the investigator had used the proton mrs to evaluate the lipid and water spectra of the femoral head and revealed its significance in predicting avascular necrosis of the femoral head. according to the above research literature, the investigators considered further investigation of the proton mrs in evaluating the musculoskeletal system.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of acquired immunodeficiency syndrome (aids) * normal volunteers exclusion criteria: * aids patients with newly developed neoplasms

Keywords: acquired immunodeficiency syndrome lipodystrophy mr spectroscopy
brain-computer interface rehabilitation and virtual environments in functional neurological disorder (brave-fnd)

Conditions: Functional Neurological Disorder; Conversion Disorder; Functional Neurological Disorders; Conversion Disorder With Weakness/Paralysis

Summary: the purpose of this study is to determine whether a course of rehabilitation using a device called a brain-computer interface can change the level of control people feel over bodily movements, in functional neurological disorder.


Eligibility criteria:
inclusion criteria: * dsm5 diagnosis of motor fnd (limb weakness, gait disorder, tremor or dystonia) from a neurologist and/or neuropsychiatrist. * moderate or severe symptoms (≥4 on clinical global impression severity (cgi-s) scale). * able to tolerate vr and bci use. * age 18 - 60 years. * english speaking. exclusion criteria: * current diagnosis of epilepsy, severe depression, bipolar disorder, psychotic disorder, personality disorder, or drug/alcohol dependence/harmful use (defined as meeting dsm-5 criteria) (mini international neuropsychiatric interview \[mini\] 7.0). positive diagnoses on the mini will be subject to confirmation at clinical interview by a psychiatrist. * current diagnosis of epilepsy, autistic spectrum disorder, dementia, learning disability (defined as meeting dsm-5 criteria) based on clinical interview by a psychiatrist. * a pacemaker, implantable cardioverter-defibrillator or any other implanted electronic or metallic device. * current pregnancy. * non-registration with a gp or failure to consent to sharing of the gp summary care record and any psychiatric assessments held. * those enrolled in another clinical or research study. * those unable to give informed consent.

Keywords: brain-computer interface rehabilitation
pilot study of the endologix fenestrated stent graft system

Conditions: Juxtarenal Aortic Aneurysm; Pararenal Aortic Aneurysm

Summary: the purpose of this study is to determine whether the endologix fenestrated stent graft system is safe and feasible in the endovascular repair of juxtarenal or pararenal aortic aneurysm.


Eligibility criteria:
inclusion criteria: * informed consent understood and signed and pt agrees to all follow-up visits; * abdominal aortic aneurysm with diameter ≥5cm or ≥4cm which has increased by 0.5cm or more in the past six months * adequate iliac/femoral access compatible with the required delivery systems * non-aneurysmal infrarenal aortic neck \<15mm in length * most caudal renal artery to aortoiliac bifurcation length at least 70mm * proximal non-aneurysmal aortic neck below the sma with: diameter 18 to 34 mm; length at least 15 mm; angle (clock face) \<60° to the aneurysm sac; * angle \<60° (clock face) between the sma and celiac artery * renal arteries both distal to the sma by 0-35mm, within 30mm of each other axially, with 4 to 8mm lumen diameter, and with clockface angle of 90° to 210° to each other * iliac anatomy suitable for commercial bifurcated stent graft; * minimum 3cm overlap achievable between fenestrated and bifurcated stent grafts exclusion criteria: * life expectancy \<1 year as judged by the investigator; * psychiatric or other condition that may interfere with the study; * participating in the enrollment or 30-day follow-up phase of another clinical study; * known allergy to any device component; * coagulopathy or uncontrolled bleeding disorder; * contraindication to contrast media or anticoagulants; * ruptured, leaking, dissecting, or mycotic aneurysm; * serum creatinine (s-cr) level \>2.0 mg/dl; * traumatic vascular injury; * active systemic or localized groin infection; * connective tissue disease (e.g., marfan's syndrome); * recent (within prior three months) cerebrovascular accident or myocardial infarction; * prior renal transplant; * length of either renal artery to be stented \<13mm; * significant occlusive disease or calcification of either renal artery; * an essential accessory renal artery; * indispensable inferior mesenteric artery; * untreated aneurysmal disease of the descending thoracic aorta; * clinically significant mural thrombus circumferentially in the suprarenal segment; * prior iliac artery stent implanted that may interfere with delivery system introduction; * unsuitable vascular anatomy * pregnancy (female patient of childbearing potential only)

Keywords: aneurysm renal stent juxtarenal pararenal
effect of local application of boron on diabetic foot ulcers

Conditions: Diabetic Foot Ulcer

Summary: boron as a naturally occurring element has some metabolic and inflammatory actions. the antibacterial activity against gram negative bacteria is also known. boron deficiency is shown to be related with impaired wound bone healing in rats. therefore, special wound care formulas containing boron may have some positive effect on wound healing of the patients with diabetic foot ulcers.

local treatment of diabetic foot ulcers: 1. classification of international working group of the diabetic foot (iwgdf) 2. pre-treatment measurements including diameter and area 3. pre-treatment laboratory values including fasting glucose, hemoglobin, hemoglobin a1c, leucocyte count and c-reactive protein 4. pre-treatment wound culture 5. treatment either by placebo gel containing polymer of carbopol ultrex (1%) or by formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely f68 2% (w/v) and f127 2% (w/v). 6. post-treatment measurements and values

Eligibility criteria:
inclusion criteria: * diabetic food ulcer classified byinternational working group of the diabetic foot (iwgdf) as grade 1 and 2 exclusion criteria: * previous vascular surgery on the side that the ulcer is present * uncontrolled diabetes mellitus * presence of osteitis, abscess, osteomyelitis, gangrene on the side that the ulcer is present * diabetic food ulcer classified byinternational working group of the diabetic foot (iwgdf) as grade 3

Keywords: diabetes mellitus foot ulcer boron wound care